International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements. The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the futur

Trial Details

NCT ID
NCT07476729
Phase
PHASE3
Sponsor
Charite University, Berlin, Germany
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Inotuzumab ozogamicin (INO)
  • Blinatumomab
Locations (sample)
  • Vienna, Austria|48.20849,16.37208
  • Ghent, Belgium|51.05,3.71667
  • Prague, Czechia|50.08804,14.42076
  • Copenhagen, Denmark|55.67594,12.56553
  • Helsinki, Finland|60.16952,24.93545

Key Eligibility Criteria

  • For all study questions:
  • Confirmed diagnosis of 1st relapsed B-cell precursor ALL
  • Patients ≥ 1 year and less than 18 years of age at diagnosis of primary ALL and less than 21 years of age at date of inclusion into the study
  • Patient enrolled in a participating center

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →